FDA approves Biocon's generic Victoza, a fifth liraglutide copy
Another generic version of Victoza is cleared for the US market, adding supplier competition for the liraglutide injection without by itself changing insurance coverage or prices.
The FDA approved an abbreviated new drug application from Biocon Pharma for liraglutide, a generic version of the brand-name drug Victoza, on March 11, 2026 [1]. The application is ANDA215245, and the approval record lists a first marketing date of April 25, 2026 [1].
The approved product is a subcutaneous solution at 18 mg per 3 mL, or 6 mg per mL, and it is listed for prescription use [1]. Its therapeutic equivalence code is AP1, and it is not listed as a reference drug or a reference standard, designations that go with an originator product rather than a generic [1]. The product code is 70377-094, with package codes 70377-094-52 and 70377-094-53 [1]. The record names Biocon Pharma as the sponsor and Biocon Pharma Inc. as the manufacturer [1].
The drug is classified as a GLP-1 receptor agonist [1]. That is the same broad class as semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound, but liraglutide is a different molecule from both. It is also a different molecule from orforglipron, sold as Foundayo.
This is the fifth abbreviated application referencing Victoza to be approved, alongside Teva's authorized generic [1]. The approval record does not give sales figures, list prices or market share for any of those products.
Why it matters for patients
A generic copy is not the same thing as a generic for the drug a patient is taking. Liraglutide is a GLP-1 receptor agonist [1], but it is not semaglutide and not tirzepatide. Someone using Ozempic, Wegovy, Rybelsus, Mounjaro or Zepbound is not holding a liraglutide product, and this approval does not change what is in that pen or how it is prescribed.
More manufacturers making the same molecule can add supply competition. What that does to a patient's out-of-pocket cost is not settled by the approval itself. The FDA record contains no pricing information, and no insurer coverage decision or formulary placement for this product has been disclosed [1]. Whether a plan covers a generic liraglutide, and what a pharmacy charges for it, depends on the plan and the pharmacy, not on the approval alone.
The record lists a therapeutic equivalence code of AP1 [1]. It does not explain what that code means for pharmacy-level substitution, and state rules on substituting a generic for a brand at the counter vary and are not addressed in the approval record.
Because this is the fifth abbreviated application referencing Victoza, generic liraglutide was already approved before this one [1]. A new entrant in a category that already has several approved versions may matter less for availability than for the number of suppliers competing for the same prescriptions.
What happens next
The listed first marketing date is April 25, 2026 [1]. Whether Biocon brings the product to market on that date has not been reported, and no launch price, distribution plan or insurance coverage has been disclosed [1].
The FDA record does not state which strengths or package sizes other than those listed will be sold, and it does not describe any differences between this product and the other approved liraglutide generics or Teva's authorized generic [1]. Any decision about switching between liraglutide products, or between liraglutide and a semaglutide or tirzepatide product, is a medical one that the approval record does not address.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.